II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and Tolerability

II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and Tolerability

Trial to Continue to Completion

Australia, 10 July 2017: Australian biopharmaceutical company, Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce

safety and efficacy results of the interim analysis of its ongoing IMM-124E Phase II study in NASH. The objectives of this analysis

was to establish the safety of the compound and to provide a preliminary read on efficacy signals.

II trial has enrolled 133 patients with the top-line results expected in 4Q2017. The pre-planned analysis was triggered when 80

subjects completed treatment.

of the population analyzed in the interim analysis were balanced in all three groups (placebo, low dose -600mg- and high dose

-1200mg-) including sex, race, age, height, weight, BMIs, HbA1c and baseline hepatic fat fraction (HFF).

from the interim analysis are as follows:

results of the interim analysis, IMM-124E has demonstrated to be a non-absorbable, safe and tolerable compound in patients with

NASH. Early biochemical improvements in liver enzymes are noted, suggesting potential therapeutic benefit for treatment of NASH.

The DSMB recommendation was to continue the trial to completion, as there is no concern for safety or futility .

Immuron's Head of Medical commented:

are encouraged as both ALT and AST demonstrated strong correlation, suggesting an improvement of liver injury in the IMM-124E

are looking forward to completing the IMM-124E study and reporting the final results with the entire body of data by the end of

the year. We believe the additional MOA data we are generating in partnership with Duke University and SanyalBio will further

strengthen our prior data to support IMM-124E's unique mechanism of action which will assist us to design of the next phase

in our clinical program."

Thomas Liquard, added:

are encouraged by the results of this interim-analysis and are pleased by the DSMB's recommendation to continue the study

to completion. NASH is increasingly viewed as a multifactorial disease whereby the approval of several chronic therapies, with

different MOAs and used in combination, will be needed to control its long-term effects. These results support our belief that

IMM-124E is a compound with a complex MOA that has the potential to have a beneficial impact in hard-to-treat fatty-liver diseases

including NASH, ASH and Pediatric NAFLD."

Limited (NASDAQ: IMRN; ASX: IMC), is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics

for the treatment of gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development

therapeutic cycle. The Company currently markets and sells Travelan for the prevention of Travellers' Diarrhea and

its lead clinical candidate, IMM-124E, is in Phase 2 clinical trials for NASH, ASH and Pediatric NAFLD. Immuron's second

clinical stage asset, IMM-529, is targeting C. difficile Infections (CDI). These products together with the Company's

other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large

unmet need in the global immunotherapy market.

more information visit: http://www.immuron.com

FORWARD-LOOKING STATEMENTS:

press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of

1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to,

any statements relating to our growth strategy and product development programs and any other statements that are not historical

facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties

that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual

results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain,

perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and

development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical

and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the

early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual

property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking

to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations

or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.